Document Detail


Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment.
MedLine Citation:
PMID:  17286641     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: To examine concurrent buprenorphine and benzodiazepine consumption and to compare opioid toxicity symptoms induced by methadone and buprenorphine, examining factors associated with the reporting of these symptoms. DESIGN: Self-report cross-sectional survey. SETTING: Five needle syringe programmes and five opioid substitution treatment services in Melbourne, Australia. PARTICIPANTS: A total of 250 people who had experience with methadone or buprenorphine. Eligibility criteria were current or previous methadone or buprenorphine use. MEASUREMENTS: Structured questionnaire covering: demographic characteristics; current treatment and drug use; concurrent use of buprenorphine and benzodiazepines, including route of administration and source of medications; and opioid toxicity symptoms reported in association with methadone and buprenorphine consumption. FINDINGS: Of those reporting buprenorphine use, two-thirds reported concurrent benzodiazepine use, with a median dose reported of 30 mg diazepam equivalents. A greater number of opioid toxicity symptoms were reported in relation to methadone consumption compared with buprenorphine. Those reporting opioid toxicity with buprenorphine were more likely to report intravenous use compared with those reporting opioid toxicity with methadone. CONCLUSIONS: The risk of opioid toxicity appeared greater with methadone compared with buprenorphine, despite high levels of benzodiazepine consumption and injection being reported in relation to buprenorphine use. The prevalence of buprenorphine injection and the normalization of methadone-induced sedation are two findings that merit further investigation. Establishing recommendations as to the safest and most effective way to manage benzodiazepine-using people in opioid substitution treatment is necessary for the optimization of treatment for opioid dependence in polydrug-using individuals.
Authors:
Suzanne Nielsen; Paul Dietze; Nicole Lee; Adrian Dunlop; David Taylor
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-02-06
Journal Detail:
Title:  Addiction (Abingdon, England)     Volume:  102     ISSN:  0965-2140     ISO Abbreviation:  Addiction     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-03-16     Completed Date:  2007-05-21     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9304118     Medline TA:  Addiction     Country:  England    
Other Details:
Languages:  eng     Pagination:  616-22     Citation Subset:  IM    
Affiliation:
Turning Point Alcohol and Drug Centre, 54-62 Gertrude Street, Fitzroy, Victoria 3065, Australia. suzanne.nielsen@vcp.monash.edu.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Australia
Benzodiazepines / administration & dosage,  adverse effects*
Buprenorphine / administration & dosage,  adverse effects*
Drug Interactions
Drug Therapy, Combination
Female
Humans
Male
Methadone / administration & dosage*
Narcotic Antagonists / administration & dosage,  adverse effects
Narcotics / administration & dosage,  adverse effects*
Opioid-Related Disorders / rehabilitation*
Chemical
Reg. No./Substance:
0/Narcotic Antagonists; 0/Narcotics; 12794-10-4/Benzodiazepines; 52485-79-7/Buprenorphine; 76-99-3/Methadone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Does childhood sexual abuse have an effect on young adults' nicotine disorder (dependence or withdra...
Next Document:  Trajectories of adolescent alcohol and cannabis use into young adulthood.